Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10th, 2017
August 01 2017 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating
neuromuscular and neurological diseases, today announced that it
will release second quarter 2017 financial results after market
close on Wednesday, August 9, 2017. Further, Catalyst
management will host an investment-community conference call
at 8:30 a.m. EDT on Thursday, August 10th, 2017 to
discuss the financial results and to provide a corporate update.
Investors who wish to participate in the
conference call may do so by dialing (877) 407-8912 for domestic
and Canadian callers or (201) 689-8059 for international callers.
Those interested in listening to the conference call live via the
internet may do so by visiting the Investors page of the company's
website at www.catalystpharma.com and clicking on the
webcast link on the Investors home page.
A webcast replay will be available on the
Catalyst website for 30 days following the call by visiting the
Investor page of the company's website
at www.catalystpharma.com.
About Catalyst
Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating neuromuscular and
neurological diseases, including Lambert-Eaton myasthenic syndrome
(LEMS), congenital myasthenic syndromes (CMS), MuSK antibody
positive myasthenia gravis and infantile spasms. Firdapse® has
received Breakthrough Therapy Designation from the U.S. Food and
Drug Administration (FDA) for the treatment of LEMS and Orphan Drug
designation for LEMS, CMS and myasthenia gravis. Firdapse is the
first and only approved drug in Europe for symptomatic treatment in
adults with LEMS.
Catalyst is also developing CPP-115 to treat
refractory infantile spasms, and possibly refractory Tourette's
Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for
the treatment of infantile spasms by the FDA and has been granted
E.U. Orphan Medicinal Product Designation for the treatment of West
syndrome by the European Commission. In addition, Catalyst is
developing a generic version of Sabril® (vigabatrin).
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2016 and its other
filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on Catalyst's
website, or may be obtained upon request from Catalyst. Catalyst
does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contacts
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024